Evidence map›Paper›PMID 41334111›Full record

ArticleClinical and translational radiation oncology2026

The evolution of cardiac changes after breast cancer adjuvant radiotherapy - A six-year follow-up study.

Mikko Moisander, Suvi Tuohinen, Heidi Lähdeaho, Heini Huhtala, Kjell Nikus, Vesa Virtanen, Pirkko-Liisa Kellokumpu-Lehtinen, Pekka Raatikainen, Tanja Skyttä

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mikko MoisanderFaculty of Medicine and Health Technology, Tampere University, PO Box 100, 33014 Tampere, Finland.
Suvi TuohinenHeart Hospital, Tampere University Hospital, PO Box 2000, 33521 Tampere, Finland.
Heidi LähdeahoHeart Hospital, Tampere University Hospital, PO Box 2000, 33521 Tampere, Finland.
Heini HuhtalaFaculty of Social Sciences, Tampere University, PO Box 100, 33014 Tampere, Finland.
Kjell NikusFaculty of Medicine and Health Technology, Tampere University, PO Box 100, 33014 Tampere, Finland.
Vesa VirtanenHeart Hospital, Tampere University Hospital, PO Box 2000, 33521 Tampere, Finland.
Pirkko-Liisa Kellokumpu-LehtinenFaculty of Medicine and Health Technology, Tampere University, PO Box 100, 33014 Tampere, Finland.
Pekka RaatikainenHeart and Lung Center, Helsinki University Central Hospital and Helsinki University, PO Box 100, 00029 Helsinki, Finland.
Tanja SkyttäFaculty of Medicine and Health Technology, Tampere University, PO Box 100, 33014 Tampere, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This prospective study investigated the long-term effects of adjuvant radiotherapy (RT) on cardiac function and biomarkers in early breast cancer patients over a six-year follow-up. Methods: Seventy-three women treated with RT alone, without chemotherapy, were included. Cardiac radiation doses were quantified, and echocardiography and serum biomarkers (high-sensitivity cardiac troponin T [hscTnT] and N-terminal pro-brain natriuretic peptide [proBNP]) were assessed before RT and at three- and six-years post-treatment. Results: Cardiac biomarkers increased significantly during follow-up. Median hscTnT rose from 4 to 6 ng/L (p<0.001), correlating with higher radiation doses to the heart in left-sided patients. ProBNP increased from 78 to 118 ng/L (p<0.001). Left ventricular (LV) systolic function declined in left-sided patients: ejection fraction decreased from 65% to 60% (p=0.002), global longitudinal strain from -18% to -17% (p=0.006), and stroke volume from 74 to 67 mL (p=0.015). Diastolic dysfunction also progressed, with impairments in isovolumic relaxation time and left atrial ejection fraction. Aromatase inhibitor (AI) use and higher mean heart dose were associated with greater cardiac impairment. Conclusion: Subclinical deterioration in cardiac function and elevated biomarkers were evident three years after RT and persisted at six years, suggesting permanent cardiac effects. Both radiation dose and AI therapy contributed to these changes. These findings underscore the importance of long-term cardiac monitoring and support the use of sensitive imaging and biomarkers to detect early radiotherapy-induced cardiotoxicity.

Indexed as

Breast cancerCardiac biomarkersCardio-oncologyCardiotoxicityRadiotherapy

Identifiers

PMID41334111
PMCPMC12666111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.